Chiesi Licenses Second Drug to GB Therapeutics
Business Review Editor
Abstract
Chiesi Farmaceutici exclusively licensed its CHF1512/GT1512 drug to GB Therapeutics. The drug is a combination of melevodopa hydrochloride and carbidopa for the treatment of Parkinson’s disease.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.